[The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome].

H. Liu; Zonghong Shao; L P Jing

[The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome].

H. Liu, Zonghong Shao, L P Jing

In: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2001 · vol. 22(11) , pp. 581–3 · PMID:11855146 · W185916696

article OA: closed CC0 ⤵ 3 in-corpus citations

View on OpenAlex View on PubMed

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

Cyclosporin A combined with conventional treatment improved complete response rates and reduced relapse rates in patients with autoimmune hemolytic anemia and Evans syndrome compared to conventional treatment alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To test the therapeutic effectiveness of cyclosporin A (CsA) in combination with corticosteroid in the treatment of autoimmune hemolytic anemia(AIHA) and Evans syndrome. METHODS: Forty-four cases of AIHA and Evans syndrome were treated with CsA in combination with a conventional regimen (prednisone + danazol) (18 cases) or conventional regimen alone(26 cases). RESULTS: The complete response rate of CsA group (88.9%) was higher than that of conventional regimen group (57.7%) (P < 0.05), and the relapse rate was lower (3.3% vs 70%) (P < 0.01). CONCLUSION: CsA in combination with conventional regimen can improve the complete response rate and reduce relapse of AIHA and Evans syndrome.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Source provenance

openalex: last seen: 2026-05-11T03:13:13.408068+00:00

License: CC0 · commercial use OK